Evidence map›Paper›PMID 40931749›Full record

ArticleOpen research Europe2024

Post-trial access practices in conducted clinical trials for Malaria, Tuberculosis, and Neglected Tropical Diseases (NTDs) across Sub-Saharan African countries:  A quantitative study.

Yemisrach Seralegne, Cynthia Khamala Wangamati, Rosemarie de la Cruz Bernabe, Ibrahim Mdala, Martha Zewdie, Hawult Taye Adane

Abstract read
In one paragraph

Article in Open research Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yemisrach SeralegneClinical trial unit, Armauer Hansen Research Institute, Addis Ababa, 1005, Ethiopia.
Cynthia Khamala WangamatiCentre for Medical Ethics, Institute of Health and Society, Faculty of Medicine, University of Oslo, Norway, Oslo, 0450, Norway.
Rosemarie de la Cruz BernabeCentre for Medical Ethics, Institute of Health and Society, Faculty of Medicine, University of Oslo, Norway, Oslo, 0450, Norway.ORCID https://orcid.org/0000-0002-4999-3117
Ibrahim MdalaDepartment of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway, Oslo, 0450, Norway.
Martha ZewdieClinical trial unit, Armauer Hansen Research Institute, Addis Ababa, 1005, Ethiopia.
Hawult Taye AdaneClinical trial unit, Armauer Hansen Research Institute, Addis Ababa, 1005, Ethiopia.ORCID https://orcid.org/0000-0002-5604-9706

Funding

Ethiopia-Emory TB Research Training ProgramD43TW009127 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Kidist Bobosha · 2013 to 2026
$3.4M
FIC NIH HHS D43 TW009127
6 · The paper itself

Abstract

Background: According to the Council of International Organizations and Medical Sciences (CIOMS) 2016, post-trial access (PTA) means ensuring that communities involved in research can benefit from the treatments, products, and knowledge developed during the study. Although laws and policies on PTA are still limited, the topic has recently gained attention as part of efforts to promote fair benefit sharing with low- and middle-income countries. In sub-Saharan Africa, where clinical trials have significantly increased over the past two decades, information on how PTA is planned and implemented remains scarce. This study examines how PTA was addressed in clinical trials for Tuberculosis (TB), Malaria, and Neglected Tropical Diseases (NTDs) conducted in the region between 2008 and 2019. Objective: The study aims to identify gaps in PTA planning and arrangements implementation, and suggest strategies for improving access to trial interventions and knowledge post-research. Method: A quantitative, cross-sectional study was conducted, using a self- administered online questionnaire to assess the PTA planning and implementation practices of Principal Investigators (PIs), co-PIs, trial coordinators, and sponsors involved in clinical trials in malaria, tuberculosis and NTDs across sub-Saharan African countries. Of the 300 invited potential participants, 37 provided complete responses. Findings: A large proportion (43%) of the study respondents did not provide PTA plans for TB, Malaria, and NTDs in clinical trials. The findings highlight an overall lack of formalized PTA policies and commitments in clinical trials for TB, Malaria, and NTDs in sub-Saharan Africa. Most of the study participants (70.3%) expressed the need for PTA training. Conclusion: Although the study offers valuable insights into PTA planning and practices, its generalizability may be limited by factors such as geographical and disease focus, reliance on self-reported data, and stakeholder representation. Despite these limitations, the study underscores an urgent need for structured PTA policy training programs, stakeholder collaboration, and effective training. Its findings can serve as a foundation for further research and policy development to enhance PTA in low-and middle-income countries (LMICs).

Indexed as

clinical trialMalariaNTDspost-trial accessTB

Identifiers

PMID40931749
PMCPMC12417983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.